Radioimmunoconjugates for treating cancer: recent advances and current opportunities

Abstract : Introduction: Radioimmunoconjugates have been used for 30 years to diagnose and treat cancer. For many years, the use of these therapeutic tools has been limited to haematological disorders, such as non-Hodgkin's lymphoma, given that they have only had a moderate effect on solid tumours. Areas covered: Recently, several strategies have revived the potential therapeutic application for radioimmunoconjugates. In this review, the authors review the advances in immunological engineering to develop new tools like monoclonal antibodies and their derivatives. Then, the authors summarize the development of radionuclides, the use of recombinant antibodies, pretargeting approaches, and dose fractionation techniques, providing opportunities for both therapeutic and diagnostic applications. Expert opinion: Radioimmunoconjugates used in nuclear medicine have entered a new era of development. These advances give rise to a variety of opportunities in the management of various cancers, where the radiolabelled antibodies may be particularly useful in immuno-specific phenotypic imaging e.g. companion diagnostics. Concerning therapeutic applications, radioimmunoconjugates have demonstrated their efficacy in the treatment of both haematological malignancies and solid tumours. Recent procedural developments are of great interest in optimising oncological targeted therapies. In the field of cancer theranostics, we believe that radioimmunoconjugated compounds are likely to play a large part in near future. ARTICLE HISTORY
Type de document :
Article dans une revue
Expert Opinion on Biological Therapy, Informa Healthcare, 2017, 17 (7), pp.813 - 819. 〈10.1080/14712598.2017.1322577〉
Liste complète des métadonnées

Littérature citée [57 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-01635514
Contributeur : Elizabeth Bernardo <>
Soumis le : mercredi 15 novembre 2017 - 11:47:09
Dernière modification le : jeudi 5 avril 2018 - 10:37:03

Fichier

 Accès restreint
Fichier visible le : jamais

Connectez-vous pour demander l'accès au fichier

Identifiants

Collections

Citation

Mickael Bourgeois, Clément Bailly, Mathieu Frindel, François Guérard, Michel Chérel, et al.. Radioimmunoconjugates for treating cancer: recent advances and current opportunities. Expert Opinion on Biological Therapy, Informa Healthcare, 2017, 17 (7), pp.813 - 819. 〈10.1080/14712598.2017.1322577〉. 〈inserm-01635514〉

Partager

Métriques

Consultations de la notice

48